Phase i study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2136-2142

  Byrd, John C ^a   Kipps, Thomas J ^b   Flinn, Ian W ^c   Cooper, Maureen ^d   Odenike, Olatoyosi ^e   Bendiske, Jennifer ^f   Rediske, John ^f   Bilic, Sanela ^f   Dey, Jyotirmoy ^f   Baeck, Johan ^f   O'Brien, Susan ^g  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Section of Medical Oncology   (United States)

^d St Francis Cancer Research Foundation   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chronic lymphocytic leukemia; CLL; combination therapy; efficacy; lucatumumab

Indexed keywords

AMYLASE; CD40 ANTIGEN; LUCATUMUMAB; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER STAGING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNOGENICITY; INSOMNIA; LEUKEMIA RELAPSE; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD40; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECURRENCE;

EID: 84861754264     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.681655     Document Type: Article

References (44)

1. Ries LAG, Melbert D, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD. Based on November 2006 SEER data submission, posted to the SEER web site, 2007. Available from: http://seercancergov/csr/1975-2004/
2. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
4. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-447. (Pubitemid 26341010)
5. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647. (Pubitemid 33126814)
6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
7. Mayr C, Speicher MR, Kof er DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742-751. (Pubitemid 43076401)
8. Johnson S, Smith AG, Lof er H, et al. Multicentre prospective randomised trial of f udarabine versus cyclophosphamide, doxo-rubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432-1438. (Pubitemid 26161205)
9. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
10. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of f udarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325.
11. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of f udarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
12. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to f udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
13. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with f udarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349-1355.
14. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of f udarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14. (Pubitemid 36025880)
15. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed f udarabine: results of a large international study. Blood 2002;99:3554-3561. (Pubitemid 34534522)
16. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
17. Coifier B, Lepretre S, Pedersen LM, et al. Safety and effcacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-1100. (Pubitemid 351213387)
18. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological prof le of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994;8:1640-1645. (Pubitemid 24323778)
19. Pu QQ, Bezwoda WR. Interleukin-4 prevents spontaneous in-vitro apoptosis in chronic lymphatic leukaemia but sensitizes B-CLL cells to melphalan cytotoxicity. Br J Haematol 1997;98:413-417. (Pubitemid 27345118)
20. Francia di Celle P, Mariani S, Riera L, et al. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996;87:4382-4389.
21. Moreno A, Villar ML, Camara C, et al. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 2001;97:242-249. (Pubitemid 32065676)
22. Jurlander J, Lai CF, Tan J, et al. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997;89:4146-4152. (Pubitemid 27220963)
23. Trentin L, Cerutti A, Zambello R, et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996;87:3327-3335.
24. de Totero D, Meazza R, Capaia M, et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with dif erential activation of the JAK/STAT and ERK1/2 pathways. Blood 2008;111:517-524.
25. Trentin L, Zambello R, Agostini C, et al. Expression and functional role of tumor necrosis factor receptors on leukemic cells from patients with type B chronic lymphoproliferative disorders. Blood 1993;81:752-758. (Pubitemid 23040868)
26. Digel W, Stefanic M, Schoniger W, et al. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989;73:1242-1246. (Pubitemid 19107429)
27. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-1020. (Pubitemid 41076448)
28. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703-710. (Pubitemid 46105972)
29. Enzler T, Kater AP, Zhang W, et al. Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell-turnover that can be of set by extrinsic CD257 to accelerate disease progression. Blood 2009;114:4469-4476.
30. Haiat S, Billard C, Quiney C, et al. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118:281-292.
31. Kern C, Cornuel J F, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688. (Pubitemid 38145555)
32. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-2206. (Pubitemid 30108780)
33. Kitada S, Zapata JM, Andreef M, et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995-1004. (Pubitemid 29463014)
34. Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753-763.
35. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391-1400. (Pubitemid 39136749)
36. Romano M F, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits f udarabine-induced apoptosis in B chronic lympho-cytic leukemia cells. Blood 1998;92:990-995. (Pubitemid 28355483)
37. Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711-720.
38. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990-4997. (Pubitemid 26189840)
39. Vosters O, Beuneu C, Nagy N, et al. CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inf ammatory cytokines. Diabetologia 2004;47:660-668. (Pubitemid 38658368)
40. Klein D, Barbe-Tuana F, Pugliese A, et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005;48:268-276. (Pubitemid 40543298)
41. Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-4377.
42. Furman RR, Forero-Torres A, Shustov A, et al. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:228-235.
43. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a def ciency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984;63:305-309. (Pubitemid 14188874)
44. Lapalombella R, Gowda A, Joshi T, et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848-855. ):